| Literature DB >> 31487762 |
Chris George Cura Pales1, Sanghyun An2, Jan Paolo Cruz3,4, Kwangmin Kim2,5, Youngwan Kim2.
Abstract
Low anterior resection syndrome (LARS) refers to a disturbance of bowel function that commonly manifests within 1 month after rectal cancer surgery. A low level of anastomosis and chemoradiotherapy have been consistently found to be risk factors for developing LARS. Thorough history taking and physical examination with adjunctive procedures are essential when evaluating patients with LARS. Anorectal manometry, fecoflowmetry, and validated questionnaires are important tools for assessing the quality of life of patients with LARS. Conservative management (medical, physiotherapy, transanal irrigation), invasive procedures (neuromodulation), and multimodal therapy are the mainstay of treatment for patients with LARS. A stoma could be considered when other treatment modalities have failed. An initial meticulous surgical procedure for rectal cancer, creation of a neorectal reservoir during anastomosis, and proper exercise of the anal sphincter muscle (Kegel's maneuver) are essential to combat LARS. Pretreatment counseling is a crucial step for patients who have risk factors for developing LARS.Entities:
Keywords: Bowel function; Diagnosis; Rectal neoplasm; Surgical procedures; Therapy
Year: 2019 PMID: 31487762 PMCID: PMC6732333 DOI: 10.3393/ac.2019.08.10
Source DB: PubMed Journal: Ann Coloproctol ISSN: 2287-9714
Selected literature on functional outcomes after a low anterior resection
| Study | Surgical procedure | Bowel function evaluation | Functional outcomes |
|---|---|---|---|
| Kakodkar et al. [ | LAR with TME (CAA) | Anorectal manometry | Frequency: 3.3 ± 0.17 |
| Wexner continence questionnaire | MBP (cmH2O): 37.7 ± 0.41 | ||
| MSP (cmH2O): 76.6 ± 0.54 | |||
| MTV (mL): 146.3 ± 4.06 | |||
| Compliance (mL/cmH2O): 3.83 ± 0.27 | |||
| RAIR – absent in half | |||
| Wexner score: 4.37 ± 0.2 | |||
| Akagi et al. [ | ISR | Anorectal manometry | Frequency: 5.1 (1–20) |
| Wexner continence questionnaire | MBP (cmH2O): 41 (4–84) | ||
| MSP (cmH2O): 178 (20–346) | |||
| Wexner score: 7.2 (1–20) | |||
| Patient satisfaction (%) | |||
| -Very low 8.8 | |||
| -Medium 19.3 | |||
| -Perfect 71.9 | |||
| Dulskas and Samalavicius [ | LAR with TME | Anorectal manometry | Frequency: 3.3 ± 0.17 |
| Wexner continence questionnaire | MBP (cmH2O): 43 ± 5.7 | ||
| MSP (cmH2O): 100 ± 8.9 | |||
| MTV (mL): 140 ± 8.2 | |||
| Wexner score: 6.3 (mean score) | |||
| Shibata et al. [ | LAR with TME (CAA and intraoperative radiation) | MSKCC Sphincter Function Scale | More than one-half of the patients treated by sphincter preservation, EBRT, IORT, and chemotherapy had an unfavorable functional outcome. |
| -EORTC QLQ-C30 | |||
| Emmertsen et al. [ | LAR | LARS score | Higher risk of major LARS with neoadjuvant therapy af- ter TME and with temporary diverting stoma |
| -TME vs. PME | European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 | LARS score has high sensitivity and specificity for iden- tifying patients with major bowel dysfunction causing impairment of QoL | |
| -Neoadjuvant vs. no Neoadjuvant | |||
| Juul et al. [ | LAR (no stoma) | LARS score | Patients with major LARS fare substantially worse in 7 of the 8 EORTC QLQ-C30 compared with patients with no/minor LARS. |
| EORTC QLQ-C30 | |||
| Qin et al. [ | LAR | LARS score | nCRT had a higher risk of developing major LARS than nCT alone |
| -nCRT vs nCT | Postoperative pelvic MRI |
LAR with TME, low anterior resection with total mesorectal excision; CAA, coloanal anastomosis; ISR, intersphincteric resection; MSKCC, Memorial Sloan-Kettering Cancer Center bowel function instrument; (EORTC) QLQ-C30, European organization for research and treatment of cancer; LARS score, low anterior resection syndrome score; MRI, magnetic resonance imaging; MBP, mean basal pressure; MSP, mean squeezing pressure; MTV, maximum total volume; RAIR, rectoanal inhibitory reflex; EBRT, external beam radiation therapy; IORT, intraoperative radiation therapy; QoL, quality of life; nCRT, neoadjuvant chemoradiotherapy; nCT, neo-adjuvant chemotherapy.